BioSpace News Archive

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor pathway diseases, announced a proposed public offering of $100 million of shares of its common stock.

Neuron23™ Inc. and QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a collaboration to develop a companion diagnostic for Neuron23’s LRRK2 inhibitor for Parkinson’s disease.

Rockwell Medical, Inc. today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of stock options to purchase an aggregate of 66,000 shares of the Company’s common stock.

QIAGEN (NYSE:QGEN; Frankfurt Prime Standard: QIA) and Neuron23 Inc. today announced the signing of an agreement to develop a companion diagnostic for Neuron23’s brain penetrant leucine-rich repeat kinase (LRRK2) inhibitor for Parkinson’s disease.

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller, Chief Financial Officer, will participate in a fireside chat at the upcoming Guggenheim Nantucket Therapeutics Conference.

Pharma-Bio Serv, Inc. announced that revenues for the three and nine months ended July 31, 2022 were approximately $4.8 and $14.8 million, respectively.

Qualigen Therapeutics, Inc. (Nasdaq: QLGN), today announces the presentation of two posters on the Company’s lead compound, QN-302, at the American Academy of Cancer Research’s (AACR) 8th Special Conference on Pancreatic Cancer being held on September 13-16, 2022 in Boston.

Travere Therapeutics, Inc. announced that on September 10, 2022, the Compensation Committee of its Board of Directors granted inducement equity grants to 16 new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 79,600 shares of its common stock.

ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, announced today it will participate in the Lytham Partners Fall 2022 Investor Conference taking place virtually on September 28-29, 2022.

Astrocyte Pharmaceuticals Inc., a private drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, today provided an update on the preclinical and clinical development of its lead drug candidate, AST-004, in preclinical brain injury studies and in an ongoing clinical Phase 1 study.